Corona Remedies Expands Cardio & Women's Health With Bayer Deal

Pharma company Corona Remedies is set to further bolster its presence in cardiology and hormones for women with seven major brands purchased from Bayer's Indian pharmaceuticals division.

The acquisition would take effect on July 16, 2025, and is expected to be finalized within a few months of the company submitting its IPO draft papers worth ?800 crore to SEBI in April 2023. 

The acquisition involves Noklot, one of the leading anti-platelet monotherapy agents in the ?1,507 crore anti-platelet market in India, which is expected to grow robustly at 8% per annum. In women's health, Corona's purchase will deepen its footprint in gonadotrophin and progesterone therapies, collectively worth ?1,862 crore in June 2025. The newly purchased brands are Fostine, Luprofact, Menodac, Ovidac, Spye, and Vageston.

The deal's financials aren't publicly known, but the strategic merits are clear. As a noteworthy national marketing network, Corona expects to emulate the expansion of these legacy brands beyond metros to deeper rural markets, which has been a hallmark of its recent brand acquisition strategy.

Also Read: Blockchain for Secure Pharmaceutical Supply Chains - 2025 & Beyond

This is Corona's fourth acquisition from a global pharma player, and follows on the earlier acquisitions from Sanofi, Abbott, and GSK. The timing is fortuitous for Corona to elevate its growth prior to an initial public offering (IPO), and posture itself as serious player in therapeutic segments where larger and more established players have historically rested on their competitive advantages.

The acquisition is notable as the sector considers a competitive trajectory, given varying IPO trajectories, and it shows Corona's plans to scale through aggressive brand consolidation and highly focused therapeutic expansion, which is becoming a growing trend in India's competitive pharmaceutical landscape.